Mr. Michael McFadden reports

ALPHA COGNITION FILES U.S. PATENT APPLICATION COVERING AN ALPHA-1062 ORAL FORMULATION TO TREAT MILD TO MODERATE ALZHEIMER'S DISEASE

Alpha Cognition Inc. has filed a new composition-of-matter patent that secures broad protection for its lead asset, Alpha-1062, currently under review by the U.S. Food and Drug Administration (FDA) for mild to moderate Alzheimer's disease.

The present composition-of-matter patent application is filed for approval with the USPTO and may be extended to pursue protection throughout the world and, if approved, will secure composition-of-matter protection for an oral formulation of Alpha-1062. The filing was based on novel and unexpected findings in the clinical trial work the company completed and further demonstrates the uniqueness of Alpha-1062. If approved, the patent will provide protection for Alpha-1062 into 2044, adding to other patent protection that currently protect Alpha-1062 through 2042.

"Filing this patent application is an important component of our strategy to ensure broad protection for Alpha-1062, a next generation treatment option for patients suffering from mild-to-moderate Alzheimer's Disease. Grant of the patent will provide protection through 2044 in the United States, and will allow our team to maximize the potential that Alpha-1062 holds for patients and healthcare providers," stated Alpha Cognition's CEO, Michael McFadden.

About Alpha Cognition Inc.

Alpha Cognition Inc. is a clinical stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury ("mTBI"), for which there are currently no approved treatment options.

Alpha-1062, is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. Alpha-1062's active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. Alpha-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer's dementia.

An intranasal formulation of Alpha-1062 has demonstrated potent preservation brain structure and function in a preclinical model of moderate TBI, where enhanced recovery from the brain injury was also seen. The intranasal formulation is currently being evaluated for its ability to provide protection from a military relevant model of repeated mild TBI, in a program sponsored by the US Department of Defense.

We seek Safe Harbor.